Merck & Co., Inc. (NYSE:MRK) Holdings Decreased by Personal CFO Solutions LLC

Personal CFO Solutions LLC decreased its holdings in shares of Merck & Co., Inc. (NYSE:MRKFree Report) by 1.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 43,397 shares of the company’s stock after selling 656 shares during the quarter. Merck & Co., Inc. accounts for approximately 0.8% of Personal CFO Solutions LLC’s holdings, making the stock its 21st biggest position. Personal CFO Solutions LLC’s holdings in Merck & Co., Inc. were worth $4,731,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank acquired a new position in shares of Merck & Co., Inc. during the 4th quarter worth about $3,108,366,000. Wellington Management Group LLP increased its position in Merck & Co., Inc. by 6.7% in the third quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock worth $8,487,472,000 after purchasing an additional 5,196,914 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Merck & Co., Inc. by 14.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 36,682,866 shares of the company’s stock worth $3,966,029,000 after purchasing an additional 4,731,152 shares during the last quarter. Bank of Nova Scotia grew its holdings in Merck & Co., Inc. by 352.2% during the fourth quarter. Bank of Nova Scotia now owns 3,144,632 shares of the company’s stock valued at $342,814,000 after purchasing an additional 2,449,211 shares during the period. Finally, Public Employees Retirement Association of Colorado raised its stake in Merck & Co., Inc. by 29,914.1% during the 4th quarter. Public Employees Retirement Association of Colorado now owns 2,410,732 shares of the company’s stock worth $262,818,000 after buying an additional 2,402,700 shares during the period. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Stock Up 0.1 %

NYSE:MRK traded up $0.15 on Friday, hitting $130.67. The stock had a trading volume of 4,945,599 shares, compared to its average volume of 7,277,381. The firm’s fifty day simple moving average is $128.51 and its two-hundred day simple moving average is $121.47. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25. Merck & Co., Inc. has a 1 year low of $99.14 and a 1 year high of $133.10. The stock has a market cap of $330.96 billion, a P/E ratio of 145.19, a price-to-earnings-growth ratio of 2.52 and a beta of 0.39.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its quarterly earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.13. Merck & Co., Inc. had a net margin of 3.76% and a return on equity of 14.05%. The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.21 billion. During the same quarter last year, the business posted $1.40 EPS. Merck & Co., Inc.’s quarterly revenue was up 8.9% compared to the same quarter last year. Analysts predict that Merck & Co., Inc. will post 8.64 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 8th. Investors of record on Monday, June 17th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Monday, June 17th. This represents a $3.08 dividend on an annualized basis and a yield of 2.36%. Merck & Co., Inc.’s dividend payout ratio is 342.22%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on MRK shares. Argus upgraded Merck & Co., Inc. to a “strong-buy” rating in a report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 target price on shares of Merck & Co., Inc. in a research note on Tuesday. Berenberg Bank increased their price objective on Merck & Co., Inc. from $140.00 to $143.00 and gave the company a “buy” rating in a report on Monday, April 8th. Truist Financial upped their price target on shares of Merck & Co., Inc. from $142.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Finally, Societe Generale cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 price objective on the stock. in a research report on Monday, March 11th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and a consensus target price of $133.00.

View Our Latest Report on Merck & Co., Inc.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.